According to the Institute for Clinical and Economic Review and its California affiliate, the value of new HCV drugs Sovaldi sofosbuvir from Gilead Sciences Inc. and Olysio simeprevir from Johnson & Johnson is low because their benefits are not worth the costs.

The new drugs offer patients big improvements in cure rates, side effects and convenience compared with first-generation protease inhibitors that have become standard of care (see Cover Story).